Download biomedica product list
Our ELISA Kits Reach Customers Worldwide
We are represented in more than 60 countries, ensuring worldwide product availability and customer support through trusted partnerships with carefully selected local distributors across nearly every continent. Wherever you are, we are ready to support your research goals.
With more than 40 years of experience, we specialize in the development and manufacture of high-quality ELISA assay kits for clinical research biomarkers.
Explore our ELISA assay product brochure.
Our ELISA Kits Reach Customers Worldwide – contact us!
About us
BIOMEDICA Immunoassays develops and manufactures high-quality, widely cited immunoassays for clinical and pre-clinical applications in bone and cardiorenal diseases. For selected biomarkers, BIOMEDICA has become a global leader, including Sclerostin, free sRANKL, OPG, and NT-proCNP.
All BIOMEDICA ELISA assays are fully validated according to international quality guidelines. The assays include ready-to-use serum-based calibrators and controls, helping researchers generate biologically reliable data.
Features & Benefits of BIOMEDICA ELISA Assay Kits
Trusted – cited in more than 2,500 publications
Highly specific – developed with well-characterized, epitope-mapped antibodies
Fully validated – comprehensive validation according to international quality guidelines
Convenient – ready-to-use, color-coded reagents with controls included
Biomarker ELISA Assays for Bone-Mineral Metabolism & Cardio-Renal Diseases
–Intact FGF23 ELISA Kit | BI-20700
–FGF23 (C-terminal) multi-matrix ELISA Kit | BI-20702
–FREE soluble RANKL HS ELISA | BI-20462
–OPG ELISA Kit (Human Osteoprotegerin) | BI-20403
–Rat NT-proBNP ELISA | BI-1204R
Selected citations
Profiling bone status indices reveals evidence of a low-turnover bone phenotype in type 2 diabetes: findings from the DiaFALL cohort. Rasmussen, Kvist, Bech, Lykkeboe, Starup-Linde, Handberg, van den Bergh, Vestergaard; Osteoporos Int (2026) .
Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Jalava, Heino, Nuutila, Virtanen, Ivaska; Clin Endocrinol (Oxf) (2026) 104 (2), 130-138 .
Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth. Espiner, E., Prickett, T., Olney, R., 2018. Horm Res Paediatr 90, 345–357.
Subclinically low BMD in young men is associated with compromised bone microarchitecture and lower lean mass. Goulart, Kargl, Sterczala, Sekel, Wunderlich, Mroz, Lovalekar, Martin, Fazeli, Cauley, O’Leary, Greeves, Koltun, Nindl. J Endocr Soc (2026) 10 (3), bvag003.